

July 12, 2021

## Enzymatica and STADA extend agreement on ViruProtect to Vietnam

**Enzymatica has licensed to STADA exclusive rights to market and sell ViruProtect® (ColdZyme®) in Vietnam. The agreement builds on the two companies' existing successful partnership to market ViruProtect, a medical device for treating and alleviating common colds, in approximately 40 countries worldwide. Extending the partnership will leverage Enzymatica's technological expertise with STADA's substantial commercial footprint and sales and marketing infrastructure in Vietnam through its STADA Vietnam and Pymepharco subsidiaries.**

Enzymatica AB and STADA are expanding their successful commercial partnership for ViruProtect to cover Vietnam. Under the terms of the extended partnership, Enzymatica will supply ViruProtect for STADA Vietnam to distribute and market in Vietnam through an extensive marketing and sales network. Through its STADA Vietnam and Pymepharco subsidiaries, STADA is among the 10 leading companies in Vietnam's pharmaceuticals sector, with nationwide coverage of both retail and hospital channels. With a growing portfolio of non-prescription brands, the company intends to become a top-five player in Vietnam's consumer healthcare market.

The agreement builds on the two companies' existing successful partnership to market ViruProtect, a medical device mouth spray for treating and alleviating common colds, in more than 40 countries worldwide. Following local registration, STADA intends to introduce ViruProtect in Vietnam next year.

“As a major investor in Vietnam's pharmaceutical sector for more than 20 years, STADA is ideally placed to bring this innovative product to consumers and pharmacists as a go-to-partner in Vietnam. By combining the introduction of STADA's international brands such as Natures Aid and Walmark food supplements with licensing partnerships for appealing products such as ViruProtect, STADA is increasingly offering Vietnam's pharmacists and consumers an attractive range of consumer healthcare brands they can trust”, said Carsten Cron, STADA's Head of Emerging Markets.

Estimates value Vietnam's growing consumer healthcare market at around EUR 2 billion per year. Within the Ear-Nose-Throat (ENT) category of primary care, pharynx supportive therapies generate annual sales of more than EUR 20 million. Through the innovative ViruProtect mouth spray, STADA intends to offer an attractive alternative to both oral topical or solution products as a pioneer in healthy ENT care for the Vietnamese public.

“With STADA's strong market position and high ambitions in Vietnam, we see good opportunities for ViruProtect to become a well-established brand in the cough & cold market,” said Kristoffer Ahlerup, Commercial Director at Enzymatica.

Enzymatica AB (publ)

Ideon Science Park, SE-223 70 Lund, Sweden

Tel: +46 (0)46-286 31 00, Web: enzymatica.se

VirusProtect – also marketed as ColdZyme® in certain markets – is a class III medical device containing glycerol and the natural enzyme trypsin. In *in vitro* studies, the cold spray was effective against over 90 % of main cold-causing viruses<sup>1</sup>. Studies have shown that the spray can shorten the duration of common cold in comparison to placebo<sup>2</sup>.

The information in this press release is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 3 pm CET on July 12, 2021.

**FOR MORE INFORMATION, PLEASE CONTACT:**

Kristoffer Ahlerup, Commercial Director, Enzymatica AB  
Phone: +46 (0)735 33 68 36 | Email: [kristoffer.ahlerup@enzymatica.com](mailto:kristoffer.ahlerup@enzymatica.com)

Stefan Olsson, Communication Manager, Enzymatica AB  
Phone: +46 (0)708 55 11 85 | Email: [stefan.olsson@enzymatica.com](mailto:stefan.olsson@enzymatica.com)

STADA Arzneimittel AG / Media Relations  
Stadastrasse 2-18 / 61118 Bad Vilbel / Germany  
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: [press@stada.de](mailto:press@stada.de) Or visit us on the Internet at [www.stada.com/press](http://www.stada.com/press)

**ABOUT ENZYMATICA AB**

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company's first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about 30 markets on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: [www.enzymatica.com](http://www.enzymatica.com) and [www.enzymatica.se/en/section/media/press-releases](http://www.enzymatica.se/en/section/media/press-releases)

Enzymatica's certified adviser is Erik Penser Bank. Phone: +46 (0)8 463 83 00. Email: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

**ABOUT STADA ARZNEIMITTEL AG**

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2020, STADA achieved group sales of EUR 3,010.3 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 713.3 million. As of 31 December 2020, STADA employed 12,301 people worldwide.

---

<sup>1</sup> A medical device forms a protective barrier in the throat that deactivates five major common cold viruses. B. Stefansson, A. Gudmundsdottir, M. Clarsund, Swe ENT Congress 2018

<sup>2</sup> COLDPREV – A Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Study on ColdZyme® Mouth Spray against Rhinovirus-Induced Common Cold. OJRD, 2017, 7, 125–135